Expert Review of Endocrinology and Metabolism This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Advances in the treatment of functional male hypogonadism
Expert Rev Endocrinol Metab. 2023 Dec 15:1-15. doi: 10.1080/17446651.2023.2296022. Online ahead of print.ABSTRACTINTRODUCTION: Functional hypogonadism is frequently found in obese men, particularly those with metabolic complications. Several possible therapeutic approaches could be considered.AREAS COVERED: An extensive search on Medline, Embase, and Cochrane databases was performed to retrieve the available studies assessing the change of testosterone (T) and sexual function upon dieting or physical activity programs, as well as glucagon-like peptide 1 analogues. The role of lifestyle interventions associated with T repla...
Source: Expert Review of Endocrinology and Metabolism - December 20, 2023 Category: Endocrinology Authors: Giovanni Corona Giulia Rastrelli Clotilde Sparano Linda Vignozzi Alessandra Sforza Mario Maggi Source Type: research

Knowledge and attitude on the role of lifestyle modifications in the management of diabetes in Jeddah, Saudi Arabia
CONCLUSION: The knowledge and attitude on the role of lifestyle modifications in preventing and managing T2D is moderate, implying an opportunity for innovative strategies to raise public knowledge and attitude.PMID:38117226 | DOI:10.1080/17446651.2023.2296618 (Source: Expert Review of Endocrinology and Metabolism)
Source: Expert Review of Endocrinology and Metabolism - December 20, 2023 Category: Endocrinology Authors: Abdullah A Awadh Rashed I Ibrahim Jehad H Habeeballah Abdulrahman F Gassim Sultan M Alzahrani Hassan O Bogari Anas S AlGhamdi Mohammed A Khan Source Type: research

Somatrogon injection for the treatment of pediatric growth hormone deficiency with comparison to other LAGH products
Expert Rev Endocrinol Metab. 2023 Dec 4:1-10. doi: 10.1080/17446651.2023.2290495. Online ahead of print.ABSTRACTINTRODUCTION: Somatrogon (NGENLA™) is a long-acting GH (LAGH) formulation that was approved in Canada in October 2021 for the treatment of pediatric growth hormone deficiency (GHD). Somatrogon has also received approval in Australia, Japan, the European Union, the USA, and the UK. Somatrogon is a glycoprotein that utilizes three copies of the C-terminal peptide of human chorionic gonadotropin to delay its clearance allowing for once-weekly administration.AREAS COVERED: The purpose of this article is to describe...
Source: Expert Review of Endocrinology and Metabolism - December 19, 2023 Category: Endocrinology Authors: Eric P Velazquez Bradley S Miller Kevin C J Yuen Source Type: research

Highlighting the effect of reduced training volume on maintaining hormonal adaptations obtained from periodized resistance training in sarcopenic older women
CONCLUSIONS: These findings suggest that performing at least one training session per week with the HIIRT protocol is crucial for maintaining hormonal adaptations in sarcopenic older women.PMID:38103186 | DOI:10.1080/17446651.2023.2294091 (Source: Expert Review of Endocrinology and Metabolism)
Source: Expert Review of Endocrinology and Metabolism - December 16, 2023 Category: Endocrinology Authors: Zeinab Hooshmandi Farhad Daryanoosh Amir Hossein Ahmadi Hekmatikar D Maryama Awang Daud Source Type: research

Glycaemic control and its associated factors among adult Omanis with type 1 diabetes mellitus: a cross-sectional survey
CONCLUSIONS: The results suggested that better glycemic control could be achieved by optimizing DSM, social support, and diabetes knowledge. Sociodemographic factors should be considered when treating individuals with T1DM to reach good glycemic control.PMID:38099952 | DOI:10.1080/17446651.2023.2295483 (Source: Expert Review of Endocrinology and Metabolism)
Source: Expert Review of Endocrinology and Metabolism - December 15, 2023 Category: Endocrinology Authors: Rajaa Al-Hadhrami Omar M Al-Rawajfah Joshua K Muliira Atika Khalaf Source Type: research

Is inverse association between lipoprotein(a) and diabetes mellitus another paradox in cardiometabolic medicine?
Expert Rev Endocrinol Metab. 2023 Dec 11:1-8. doi: 10.1080/17446651.2023.2293108. Online ahead of print.ABSTRACTINTRODUCTION: The impact of Type II Diabetes mellitus (T2DM) on cardiovascular disease (CVD) is well-established, while lipoprotein(a) [Lp(a)] has recently emerged as a recognized CVD risk factor. The rising prevalence of T2DM resulting from modern lifestyles and the development of specific Lp(a)-lowering agents brought the association between T2DM and Lp(a) in the forefront.AREAS COVERED: Despite advancements in T2DM treatment, diabetic patients remain at very-high risk of CVD. Lp(a) may, to some extent, contrib...
Source: Expert Review of Endocrinology and Metabolism - December 11, 2023 Category: Endocrinology Authors: Donatos Tsamoulis Constantine E Kosmas Loukianos S Rallidis Source Type: research

Biomarkers of response to treatment in acromegaly
Expert Rev Endocrinol Metab. 2023 Dec 11:1-11. doi: 10.1080/17446651.2023.2293107. Online ahead of print.ABSTRACTINTRODUCTION: Medical treatment of acromegaly is based in a `trial and error` approach. First-generation somatostatin receptor ligands (fg-SRL) are prescribed as first-line medical therapy to the vast majority of patients, despite lack of disease control in approximately 60% of patients. However, other drugs used in acromegaly treatment are available (cabergoline, pasireotide and pegvisomant).AREAS COVERED: In this article, we review and discuss the biomarkers of response to medical treatment in acromegaly.EXPER...
Source: Expert Review of Endocrinology and Metabolism - December 11, 2023 Category: Endocrinology Authors: Leandro Kasuki Elisa Lamback Ximene Antunes M ônica R Gadelha Source Type: research

Advancements in pharmacotherapy options for treating diabetes ‎in children and adolescents
This study compares diabetes management between pediatric and adult patients and identifies treatment challenges and gaps.AREAS COVERED: We searched PubMed and Clinicaltrails.gov databases for studies published from 2001 to 2023 on diabetes management in different age groups.EXPERT OPINION: Research shows children have lower insulin sensitivity, clearance, and β cell function than adults. The US FDA only allows insulin, metformin, and liraglutide as antidiabetic medication options for children. However, some off-label drugs, like meglitinides, sulfonylureas, and alogliptin, have demonstrated positive results in treating c...
Source: Expert Review of Endocrinology and Metabolism - December 11, 2023 Category: Endocrinology Authors: Marzieh Daniali Shekoufeh Nikfar Mohammad Abdollahi Source Type: research

Comparison of teneligliptin and other gliptin-based regimens in addressing insulin resistance and glycemic control in type 2 diabetic patients: a cross-sectional study
CONCLUSION: Teneligliptin seems to be cost-effective and safer option in T2DM subjects who were not adequately controlled with metformin and sulfonylureas. However, further prospective studies are needed.PMID:38078453 | DOI:10.1080/17446651.2023.2290486 (Source: Expert Review of Endocrinology and Metabolism)
Source: Expert Review of Endocrinology and Metabolism - December 11, 2023 Category: Endocrinology Authors: Harmanjit Singh Ravi Rohilla Shivani Jaswal Mandeep Singla Source Type: research